A Pharmacy Benefit Manager (PBM) is a third party administrator contracted by health plans, employers, unions and government entities to manage prescription drug programs. A PBM acts as a fiscal intermediary between insurers/payors and pharmacies.
Immunotherapy-related side effects can occur at any time and can affect any organ.
The FDA recently approved durvalumab (Imfinzi) for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) whose tumors are unresectable and whose disease has not progressed following treatment with chemoradiation.
QVAR RediHaler is now commercially available to patients by prescription in 40 mcg and 80 mcg strengths.
Officials with the FDA approved apalutamide (Erleada) for the treatment of patients with non-metastatic, castration-resistant prostate cancer, according to a press release. Apalutamide is the first drug approved for non-metastatic, castration-resistant prostate cancer. “In the trial supporting approval, Erleada had a robust effect on this endpoint. This demonstrates the agency’s […]
FDA officials have approved tezacaftor/ivacaftor and ivacaftor (Symdeko, Vertex Pharmaceuticals) for the treatment of cystic fibrosis (CF) in individuals aged 12 years and older.
Officials with the FDA have approved Novartis’ glatiramer acetate injection (Glatopa) 40-mg/mL for the treatment of multiple sclerosis (MS).
Facebook engages more than 2 billion people, and adults over the age of 65 are increasingly more active on the site, especially when it comes to health information. The Journal of Medical Internet Research has published an article in its January 2018 issue that looks at use of Facebook for […]
Antibiotics may become ineffective in treating E coli if antibiotic resistance continues to increase among children.
Pharmacists have once again been ranked among the most honest and ethical professionals in the United States, according to the results of the latest Gallup poll on the topic. Of the survey’s 1049 respondents, 62% rated the honesty and ethical standards of pharmacists as “high” or “very high.” This percentage […]
An innovate production method may allow health care providers to produce on-demand medicine in the near future.
Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release. Abiraterone acetate previously gained FDA approval in 2011 for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who had […]
Patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab (Darzalex, Janssen) added to the standard regimen of bortezomib (Velcade, Takeda), melphalan and prednisone, in a recent study, than patients who were treated without daratumumab in their drug combination.1 Phase 3 trial results recently […]
A new medicine for treating hemophilia B, Rebinyn Coagulation Factor X (recombinant), GlycoPEGlated, has been made available to pharmacies.
Officials with the FDA have approved 2 different fixed dose drugs indicated to treat HIV-1: Symfi Lo tablets and Biktarvy. Symfi Lo tablets are a combination of efavirenz (EFV) 400-mg, lamivudine (3TC) 300-mg, tenofovir disoproxil fumarate (TDF) 300-mg. Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir alafenamide. Symfi Lo Symfi Lo is […]
In newly-released scientific analysis and data, the FDA has indicated strong evidence of the presence of compounds in kratom that strongly bind to opioid receptors, according to a statement released by FDA Commissioner Scott Gottlieb, MD. The new data contributes to the agency’s concern about kratom’s potential for abuse. In […]
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
The FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed.
The US Food and Drug Administration has approved Allergan’s supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella […]